EU’s CHMP Expected To OK Another Biosimilar Humira

 
• By Ian Schofield

The European Medicines Agency’s CHMP is expected to give the green light to Samsung Bioepis’ biosimilar version of AbbVie’s anti-TNF-alpha Humira on June 23. Numerous other biosimilar developers have biosimilar adalimumabs under development in a bid to break into the $16bn market for the world’s top-selling drug.

Jizo deities in Kamakura
• Source: Shutterstock

More from New Products

More from Scrip